MADRID, Spain—Individualized vaccination as adjuvant therapy for patients with stage two to four resected melanoma has achieved positive and highly encouraging outcomes according to findings from the INTerpath-001: Phase 3 study reported at the European Society for Medical Oncology 2026 congress. Patients in the study were randomized to treatment with the mRNA-based neoantigen therapy intismeran autogene added to standard immune checkpoint inhibitor adjuvant therapy, and compared with a control arm of patients receiving checkpoint inhibition alone.
Georgina V Long PhD FRACP; ESMO 2026: Neoantigen mRNA Significantly Delays Recurrence in Patients with Resected Melanoma
An interview with:
Georgina V Long AO PhD MBBS FRACP, Professor of Melanoma Medical Oncology and Translational Research, Medical Director, Melanoma Institute of Australia, University of Sydney, NSW, Australia
MADRID, Spain—Individualized vaccination as adjuvant therapy for patients with stage two to four resected melanoma has achieved positive and highly encouraging outcomes according to findings from the INTerpath-001: Phase 3 study reported at the European Society for Medical Oncology 2026 congress.
Patients in the study were randomized to treatment with the mRNA-based neoantigen therapy (INT) intismeran autogene added to standard immune checkpoint inhibitor adjuvant therapy, and compared with a control arm of patients receiving checkpoint inhibition alone.
Peter Goodwin heard the details from the study’s lead investigator, Georgina V Long AO PhD MBBS FRACP, Professor of Melanoma Medical Oncology and Translational Research, Medical Director,Melanoma Institute of Australia, University of Sydney, NSW, Australia
AUDIO JOURNAL OF ONCOLOGY; Georgina V. Long, PhD FRACP
Source:
ESMO Abstract:
LBA1 - INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
Speaker
Georgina V. Long (Sydney, Australia)
Related Episodes
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f
Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer
Aan identifyable subset of patients with high-risk ER+ HER2- early breast cancer better off without chemotherapy